Neumora Therapeutics, Inc. Share Price
NASDAQ: NMRA | Micro CapNeumora Therapeutics, Inc. Stock Performance
Open $1.68 | Prev. Close $1.65 | Circuit Range N/A |
Day Range $1.62 - $1.68 | Year Range $0.83 - $3.65 | Volume 34,069 |
Average Traded $1.63 |
Neumora Therapeutics, Inc. Share Price Today
As of 9 August 2026, Neumora Therapeutics, Inc.'s share price is $1.63. The stock opened at $1.68, compared to its previous close of $1.65. During today's trading session, Neumora Therapeutics, Inc.'s share price traded between $1.62 and $1.68, with an average price of $1.65. Over the past 52 weeks, the stock has recorded a high of $3.65 and a low of $0.83. In terms of performance, Neumora Therapeutics, Inc.'s share price has declined by 53.16% over the last six months and is down 6.32% on a year-on-year basis.
Neumora Therapeutics, Inc. Share Price Chart
Neumora Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $266.33M | PE Ratio (TTM) -1.12 | Dividend Yield N/A |
EPS (TTM) $-1.45 | Revenue (TTM) N/A | Return On Equity (TTM) -228.10% |
Profit Margin N/A | Debt to Equity 0.31 | Quarterly Earnings Growth YoY 21.77% |
Neumora Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Neumora Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Neumora Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.62 | $1.63 | +1.24% |
Jul 2026 | $1.69 | $1.61 | -4.73% |
Jun 2026 | $1.85 | $1.69 | -8.65% |
May 2026 | $2.46 | $1.85 | -24.80% |
Apr 2026 | $1.99 | $2.46 | +26.48% |
Mar 2026 | $2.85 | $1.95 | -44.11% |
Feb 2026 | $2.05 | $3.48 | +74.87% |
Jan 2026 | $1.79 | $1.99 | +11.48% |
Dec 2025 | $2.50 | $1.78 | -20.31% |
Nov 2025 | $3.04 | $2.24 | -25.33% |
Oct 2025 | $1.82 | $3.00 | +64.84% |
Sep 2025 | $1.81 | $1.82 | +4.60% |
NMRA Share Price FAQs
What is Neumora Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Neumora Therapeutics, Inc. stock?
What is NMRA's market capitalisation today?
What is NMRA's net income for the last quarter?
What is the 5 year returns of NMRA?
What is the high & low stock price of NMRA today?
Can I buy NMRA shares in India?